公开(公告)号：WO2010008587A2

公开(公告)日：2010-01-21

申请号：PCT/US2009/004150

申请日：2009-07-17

Applicant: STC. UNM ,  PANGANIBAN, Antonito, T. ,  MIR, Mohammad, A.

Inventor： PANGANIBAN, Antonito, T. ,  MIR, Mohammad, A.

IPC: C12N15/67 ,  C07K14/175

CPC classification number: C12N15/67 ,  C07K14/005 ,  C12N2760/12122 ,  C12N2830/60

Abstract: The present invention is directed to a system to significantly increase the expression of genes of interest, and in particular proteins and polypeptide products. Expression of hantavirus nucleocapsid protein (N) by itself results in augmented translational expression of diverse genes. The mechanism of this augmentation relies on the ability of N to replace the cellular cap binding complex to attain more efficient translation initiation- the result being great mRNA production and greater protein/polypeptide production. The inventors have also recently found that inclusion of a 5' untranslated leader region (viral UTR) from a viral RNA, in conjunction with N, leads to even more robust expression. This mechanism appears to involve recognition of the viral UTR by the N to provide even more robust protein production. Thus, a general strategy for expression of any gene would be to generate significant quantities of mRNA containing the viral UTR from a strong promoter, and then to allow translation of mRNA of a gene product in the presence of N. Even a modest increase in the production of commercially desirable proteins is a goal in industry.

Abstract translation: 本发明涉及显着增加感兴趣基因，特别是蛋白质和多肽产物表达的系统。 汉坦病毒核衣壳蛋白（N）本身的表达导致不同基因的翻译表达增强。 这种增强的机制依赖于N取代细胞帽结合复合物以获得更有效的翻译起始的能力 - 其结果是巨大的mRNA产量和更大的蛋白质/多肽产量。 本发明人最近还发现，将来自病毒RNA的5'非翻译前导区（病毒UTR）与N结合，导致甚至更强健的表达。 这种机制似乎涉及N识别病毒UTR以提供更强大的蛋白质生产。 因此，表达任何基因的一般策略是从强启动子产生大量含有病毒UTR的mRNA，然后允许在N存在下翻译基因产物的mRNA。甚至在 商业上期望的蛋白质的生产是工业中的目标。

公开(公告)号：WO2019173438A1

公开(公告)日：2019-09-12

申请号：PCT/US2019/020900

申请日：2019-03-06

Applicant: STC. UNM ,  CHACKERIAN, Bryce ,  REMALEY, Alan ,  AMAR, Marcelo ,  FOWLER, Alexandra

Inventor： CHACKERIAN, Bryce ,  REMALEY, Alan ,  AMAR, Marcelo ,  FOWLER, Alexandra

IPC: A61K39/385 ,  A61K47/69 ,  C12N15/63 ,  A61P3/06

Abstract: An immunogen generally includes a virus-like particle and an antigen linked to the virus-like particle. The antigen includes an antigenic portion of a polypeptide, wherein the polypeptide inhibits lipoprotein lipase (LPL) activity by binding to LPL. In some embodiments, the polypeptide is at least a portion of angiopoietin-like 3 (ANGPTL3). In other embodiments, the polypeptide is at least a portion of angiopoietin-like 4 (ANGPTL4). In other embodiments, the polypeptide at least a portion of angiopoietin-like 8 (ANGPTL8). In some embodiments, the virus-like particle is a Qbeta immunogenic carrier. In some of these embodiments, the antigen is linked to the virus-like particle through a Gly-Gly-Gly-Cys linker at the C-terminal of the antigen.

公开(公告)号：WO2019023203A1

公开(公告)日：2019-01-31

申请号：PCT/US2018/043442

申请日：2018-07-24

Applicant: STC. UNM ,  LIU, Ke, Jian Jim ,  SHEN, Jiangang

Inventor： LIU, Ke, Jian Jim ,  SHEN, Jiangang

IPC: A61K31/352 ,  A61P9/00 ,  A61P9/10 ,  A61P25/10

CPC classification number: A61P9/00 ,  A61K31/352 ,  A61K31/704 ,  A61K45/06 ,  A61P9/10 ,  A61P25/10 ,  A61K2300/00

Abstract: A composition includes two or more isoflavone compounds and a pharmaceutically acceptable carrier. In some cases, the isoflavone compounds can include calycosin, formononetin, or daidzein. The composition can be used in methods to treat a subject having at risk of having cerebral ischemia-reperfusion injury and/or hypoxia brain injury.

公开(公告)号：WO2018148537A1

公开(公告)日：2018-08-16

申请号：PCT/US2018/017613

申请日：2018-02-09

Applicant: STC. UNM ,  DURVASULA, Ravi, Venkata ,  FOO-HURWITZ, Ivy ,  CHENG, Qiuying ,  OGAUGWU, Christan

Inventor： DURVASULA, Ravi, Venkata ,  FOO-HURWITZ, Ivy ,  CHENG, Qiuying ,  OGAUGWU, Christan

IPC: C07K16/12 ,  C12N15/74

Abstract: In one aspect, a fusion antibody specifically binds to a C. difficile virulence toxin. In some embodiments, the C. difficile virulence toxin can include TcdA or TcdB. In some embodiments, the fusion antibody can include a first antibody moiety and a second antibody moiety. The first antibody moiety can include at least a fragment of a first antibody, and the second antibody moiety can include at least a fragment of a second antibody. In another aspect, a recombinant cell expresses the fusion antibody. In another aspect, a recombinant cell has activity that can be modulated by growing the recombinant cell in medium that includes cellobiose. Generally, the recombinant cell includes a heterologous polynucleotide that includes a promoter operably linked to a heterologous coding region, wherein the expression from the promoter is modulated when the recombinant cell is grown in culture medium that comprises cellobiose compared to when the recombinant cell is grown in culture medium that comprises glucose.

公开(公告)号：WO2018022154A9

公开(公告)日：2018-02-01

申请号：PCT/US2017/029180

申请日：2017-04-24

Applicant: STC. UNM

Inventor： BRUECK, Steven, R.J. ,  FEEZELL, Daniel ,  RANDALL, John ,  BUSANI, Tito ,  BALLARD, Joshua, B. ,  BEHZADIRAD, Mahmoud ,  RISHINARAMANGALAM, Ashwin Krishnan

IPC: G01Q70/08 ,  G01Q70/16 ,  B82Y35/00

Abstract: Provided is a composite metal-wide-bandgap semiconductor tip for scanning tunneling microscopy and/or scanning, tunneling lithography, a method of forming, and a method for using the composite metal-wide-bandgap semiconductor tip.

Abstract translation: 提供了一种用于扫描隧道显微镜和/或扫描的复合金属宽带隙半导体尖端，隧穿光刻，形成方法以及使用该复合金属宽带隙半导体尖端的方法

公开(公告)号：WO2016044598A1

公开(公告)日：2016-03-24

申请号：PCT/US2015/050700

申请日：2015-09-17

Applicant: STC. UNM ,  WILSON, Bridget S. ,  LIDKE, Diane ,  TAPIA, Lydia ,  SCHULYER, Mark ,  MAHAJAN, Avanika

Inventor： WILSON, Bridget S. ,  LIDKE, Diane ,  TAPIA, Lydia ,  SCHULYER, Mark ,  MAHAJAN, Avanika

IPC: C07K14/435 ,  C07K14/415 ,  C07K14/47 ,  A61K38/16 ,  A61K38/17 ,  A61K39/35 ,  A61P27/14

CPC classification number: A61K39/35 ,  A61K2039/577 ,  C07K14/415 ,  C07K14/43509 ,  C07K14/4702

Abstract: This disclosure describes recombinant hypoallergens and methods of treating allergy that involve administering a recombinant hypoallergen to a subject. Generally, the recombinant hypoallergen includes at least one amino acid modification compared to a corresponding wildtype allergen. As a result, the recombinant hypoallergen binds to IgE that specifically binds to the allergen, but induces release of histamine from basophils to a degree less than the wildtype allergen.

Abstract translation: 本公开描述了重组低过敏原和治疗过敏的方法，其涉及向受试者施用重组低通过物。 通常，与相应的野生型变应原相比，重组低过敏原包括至少一个氨基酸修饰。 结果，重组低过敏原与特异性结合变应原的IgE结合，但诱导组胺从嗜碱性粒细胞释放至小于野生型变应原的程度。

公开(公告)号：WO2013089925A1

公开(公告)日：2013-06-20

申请号：PCT/US2012/062734

申请日：2012-10-31

Applicant: STC. UNM

Inventor： DURVASULA, Ravi ,  FORSHAW, Adam

IPC: A01N25/28 ,  A01N63/02 ,  A01P1/00

CPC classification number: A01N25/26 ,  A01N25/28 ,  A01N63/00

Abstract: Novel particular-based pesticides formed from pesticidal agents encapsulated in one or more coatings wherein the coating enhances the pesticidal agent' s ability to control a pest population, and methods for making the same. In various embodiments the pesticidal agent may be a biopesticide and the coating may impart stability, protection from UV radiation and/or other environmental conditions, enhance the attractiveness of the pesticide to the pest, and/or serve to separate two different biologically incompatible pesticides within a mixture.

Abstract translation: 包封在一种或多种涂料中的杀虫剂形成的新型特定农药，其中所述涂层增强了杀虫剂控制有害生物群体的能力及其制备方法。 在各种实施方案中，杀虫剂可以是生物农药，并且涂层可以赋予稳定性，防止紫外线辐射和/或其他环境条件，增强杀虫剂对害虫的吸引力，和/或用于将两种不同生物不相容的农药分开 混合物。

公开(公告)号：WO2011139829A2

公开(公告)日：2011-11-10

申请号：PCT/US2011/034312

申请日：2011-04-28

Applicant: STC. UNM ,  KEYES, Roy, William ,  ROMANO, Christian ,  LUAN, Shuang ,  ARNOLD, Dorian, C.

Inventor： KEYES, Roy, William ,  ROMANO, Christian ,  LUAN, Shuang ,  ARNOLD, Dorian, C.

IPC: G06F19/00 ,  G06F15/16

CPC classification number: G06F19/3481 ,  G06F9/5083 ,  G06F19/00 ,  G16H50/50

Abstract: A method of calculating radiation fluence and energy deposition distributions on a networked virtual computational cluster is presented. With this method, complex Monte Carlo simulations that require expansive equipment, personnel, and financial resources can be done efficiently and inexpensively by hospitals and clinics requiring radiation therapy dose calculations.

Abstract translation: 提出了一种在网络虚拟计算群上计算辐射能量密度和能量沉积分布的方法。 通过这种方法，复杂的蒙特卡洛模拟需要广泛的设备，人员和财务资源，可以由需要放射治疗剂量计算的医院和诊所进行有效和低成本的处理。

公开(公告)号：WO2011094260A2

公开(公告)日：2011-08-04

申请号：PCT/US2011/022508

申请日：2011-01-26

Applicant: STC. UNM ,  HROMAS, Robert ,  LEITAO, Andrei ,  OPREA, Tudor, I. ,  SKLAR, Larry, A. ,  WILLIAMSON, Elizabeth, A. ,  WRAY, Justin ,  WANG, Wei

Inventor： HROMAS, Robert ,  LEITAO, Andrei ,  OPREA, Tudor, I. ,  SKLAR, Larry, A. ,  WILLIAMSON, Elizabeth, A. ,  WRAY, Justin ,  WANG, Wei

IPC: C07D215/233 ,  C07D401/04 ,  C07D401/14 ,  A61K31/47 ,  A61K31/4709 ,  A61P35/00

CPC classification number: C07D215/56 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/475 ,  A61K31/496 ,  A61K31/7048 ,  A61K45/06 ,  A61N5/1001 ,  A61N5/1045 ,  A61N2005/1087 ,  A61N2005/1098 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  A61K2300/00

Abstract: This invention relates to novel cancer treatment compositions and associated therapeutic methods. More particularly, this invention relates in part to small chemical bifunctional inhibitors of DNA replication and repair proteins Metnase and/or Intnase (also termed Gypsy Integrase, Gypsy Integrease-1, Gypsy Retransposon Integrase 1, or GIN-I) that simultaneously damage DNA, and to a therapeutic method that utilizes the inhibitors to increase the effectiveness of cancer treatment protocols, including radiation therapy. In preferred embodiments, compounds, compositions and methods of treatment of the invention are used to treat a patient suffering from leukemia (e.g. acute myeloid leukemia (AML) and related cancers. In certain aspects of such treatments, compounds, compositions and methods of treatment of the invention are administered as a monotherapy (in some cases, to patients who have exhibited resistance to Topo IIalpha inhibitors such as VP- 16), or are co-administered with a Topo IIalpha inhibitor or other anti-cancer agents as otherwise described herein or in combination with radiation therapy.

Abstract translation: 本发明涉及新的癌症治疗组合物和相关的治疗方法。 更具体地说，本发明部分涉及同时破坏DNA的DNA复制和修复蛋白Metnase和/或Intnase（也称为Gypsy整合酶，Gypsy Integrease-1，Gypsy Retransposon整合酶1或GIN-1）的小化学双功能抑制剂， 并涉及利用抑制剂来增加包括放射疗法在内的癌症治疗方案的有效性的治疗方法。 在优选的实施方案中，本发明的化合物，组合物和治疗方法用于治疗患有白血病（例如急性骨髓性白血病（AML）和相关癌症的患者）。在此类治疗的某些方面，本发明化合物，组合物和治疗 本发明作为单一疗法施用（在一些情况下，对展现对TopoIIα抑制剂如VP-16的抗性的患者），或者与本文另有描述的TopoIIα抑制剂或其它抗癌剂共同施用或 结合放射治疗。

公开(公告)号：WO2011088074A3

公开(公告)日：2011-07-21

申请号：PCT/US2011/020930

申请日：2011-01-12

Applicant: STC. UNM ,  PLUSQUELLIC, James ,  ACHARYYA, Dhruva ,  HELINSKI, Ryan, L.

Inventor： PLUSQUELLIC, James ,  ACHARYYA, Dhruva ,  HELINSKI, Ryan, L.

IPC: G06F21/02 ,  H04L9/08

Abstract: A system and methods that generates a physical unclonable function ("PUF") security key for an integrated circuit ("IC") through use of equivalent resistance variations in the power distribution system ("PDS") to mitigate the vulnerability of security keys to threats including cloning, misappropriation and unauthorized use.